Identifying and treating ROBO1−ve/DOCK1+ve prostate cancer: An aggressive cancer subtype prevalent in African American patients
Abstract
There is a need to develop novel therapies which could be beneficial to patients with prostate cancer (CaP) including those who are predisposed to poor outcome, such as African‐Americans. This study investigates the role of ROBO1‐pathway in predicting outcome and race‐based disparity in patients with CaP.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 20, 2020
- Source ID
- 10.1002/pros.24018
Entities
People
- Adrian P Mansini
- Arsheed A. Ganaie
- Ashraf Shabenah
- Badrinath R. Konety
- Christopher A. Warlick
- Elai Davicioni
- Jinhua Wang
- Li Wang
- Luke H. Hoeppner
- Marina G Ferrari
- Mohammad Saleem
- Paari Murugan
- Yibin Deng
Organizations
- National Cancer Institute
- National Institute on Minority Health and Health Disparities
- United States Department of Defense
- University of Minnesota